Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novartis
Pharma
Novartis, Neurocrine-Takeda, Enhertu—Fierce Pharma Asia
Novartis is mitigating a potential threat from the BIOSECURE Act. A Neurocrine drug from Takeda posted a trial win. Enhertu nears a HER2-low readout.
Angus Liu
Apr 26, 2024 5:45am
Day One pressures Novartis with FDA nod for novel RAF inhibitor
Apr 23, 2024 10:13pm
Novartis gears up for key expansions of 3 cancer drugs
Apr 23, 2024 3:37pm
Novartis reviews ties to China amid US biosecurity crackdown
Apr 23, 2024 11:07am
Novartis nominates ex-BMS chief Caforio as its next chair
Apr 23, 2024 2:44am
Roche touts near-complete MS suppression for injectable Ocrevus
Apr 17, 2024 11:00am